AKERO THERAPEUTICS INC
NASDAQ: AKRO (Akero Therapeutics, Inc.)
Last update: 20 hours ago44.87
-0.44 (-0.97%)
| Previous Close | 45.31 |
| Open | 45.51 |
| Volume | 1,190,603 |
| Avg. Volume (3M) | 1,097,012 |
| Market Cap | 3,575,205,632 |
| Price / Book | 4.77 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.75 |
| Total Debt/Equity (MRQ) | 4.81% |
| Current Ratio (MRQ) | 19.38 |
| Operating Cash Flow (TTM) | -230.11 M |
| Levered Free Cash Flow (TTM) | -148.48 M |
| Return on Assets (TTM) | -25.37% |
| Return on Equity (TTM) | -39.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Akero Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.30% |
| % Held by Institutions | 94.03% |
| 52 Weeks Range | ||
| Median | 75.00 (67.15%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Mar 2025 | 75.00 (67.15%) | Buy | 45.54 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2025 | Announcement | Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 |
| 23 Apr 2025 | Announcement | INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm |
| 07 Apr 2025 | Announcement | INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm |
| 28 Feb 2025 | Announcement | Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |